How much funding has Curevo Vaccine raised?

Curevo Vaccine has raised $196.0M in total funding, most recently a Series B round.

Who are Curevo Vaccine's investors?

Curevo Vaccine's investors include Janus Henderson Investors, Eli Lilly, Medicxi, Adjuvant Capital, OrbiMed, HBM Healthcare Investments.

When was Curevo Vaccine founded?

Curevo Vaccine was founded in 2017.

Where is Curevo Vaccine headquartered?

Curevo Vaccine is headquartered in Bothell, Washington, United States.

What industry is Curevo Vaccine in?

Curevo Vaccine operates in Biotech.

How many employees does Curevo Vaccine have?

Curevo Vaccine has 11-50 employees.

Curevo Vaccine

Acquired

Creating Better Vaccines

Bothell, United States · Founded 2017 · $196.0M raised

Biotech

Headquarters: Bothell, Washington
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: curevovaccine.com
Total Funding: $196.0M
Last Round: $110.0M Series BMar 2025
Rounds: 3

About

Curevo Vaccine is a clinical-stage biotechnology company founded in 2017 and headquartered in Bothell, Washington. It develops next-generation non-mRNA adjuvanted subunit vaccines targeting unmet medical needs, with its lead program amezosvatein (CRV-101) advancing through Phase 2 clinical trials for shingles and chickenpox with superior tolerability versus Shingrix.

Summary

Curevo Vaccine is a Biotech company based in Bothell, United States, founded in 2017. It has raised $196.0M in total across 3 rounds, most recently a $110.0M Series B round in Mar 2025. Investors include Janus Henderson Investors, Eli Lilly and Medicxi.